Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Study of YLB217 in Non-Dialysis Renal Anemia Patients
jRCT2080225097Phase 3Completed
- Sponsor
- YL Biologics Limited
- Start
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-arm trial of darbepoetin alfa biosimilar in anemia of renal disease, sponsored by YL Biologics Limited. Started Feb 2020; status: completed.
02
Drugs
darbepoetin alfa biosimilar
03
Conditions
anemia of renal disease
Beyond the preview
Go deeper on jRCT2080225097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225097.